Clinical Trial Update: Observational Study to Evaluate the Time to Achieving the Maintenance Dose of Zemplar® (Paricalcitol Injection) in the Treatment of Patients Suffering From End-stage Renal Disease and Severe Over-reactivity of the Parathyroid Glands

View source ↗

Summary

This completed observational study evaluated the time to achieve the maintenance dose of paricalcitol (Zemplar) in patients with end-stage renal disease and sec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease
• Hyperparathyroidism

Drugs mentioned

• Zemplar (Paricalcitol)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Kidney Failure, Chronic | Status: COMPLETED | Results posted: 2012-12-21